Document is current
Any future updates will be listed below
-
Authors
Singh, Amar https://orcid.org/0000-0002-4721-1513
Ramachandran, Sabarinathan https://orcid.org/0000-0003-2239-8083
Graham, Melanie L. https://orcid.org/0000-0002-2475-6975
Daneshmandi, Saeed https://orcid.org/0000-0001-7817-3006
Heller, David https://orcid.org/0000-0002-0461-8524
Suarez-Pinzon, Wilma Lucia
Balamurugan, Appakalai N.
Ansite, Jeffrey D. https://orcid.org/0000-0001-6241-0468
Wilhelm, Joshua J. https://orcid.org/0000-0002-6187-4874
Yang, Amy
Zhang, Ying https://orcid.org/0000-0003-3764-7329
Palani, Nagendra P. https://orcid.org/0000-0001-7701-8901
Abrahante, Juan E. https://orcid.org/0000-0002-9074-4307
Burlak, Christopher https://orcid.org/0000-0003-1715-1377
Miller, Stephen D. https://orcid.org/0000-0002-9556-0718
Luo, Xunrong https://orcid.org/0000-0001-5581-9409
Hering, Bernhard J. https://orcid.org/0000-0002-5962-7284
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UO1 AI102463)
Diabetes Research and Wellness Foundation, Transplant Division in the University of Minnesota’s Department of Surgery, and Individual philanthropy through the University of Minnesota Foundation.
- License Information
-
More Information
Article History
Received: 28 November 2018
Accepted: 9 July 2019
First Online: 2 August 2019
Competing interests
: S.R. and C.B. received research support for projects not reported in this article by Diabetes-Free, Inc., an organization that may gain or lose financially through this publication. M.L.G. is a paid consultant for Otsuka Pharmaceutical Factory, Inc. S.D.M. is a co-founder, member of the SAB and a paid consultant for Cour Pharmaceuticals Development Company; a member of the SAB and a paid consultant for NextCure Inc.; and a paid consultant for Kite Pharmaceuticals. S.D.M. and X.L. are inventors on issued patent no. US 8,734,786 B2 submitted by Northwestern University that covers the use of ECDI-fixed cell tolerance as a method for preventing allograft rejection. B.J.H. has an equity interest in and serves as an executive officer of Diabetes-Free, an organization that may commercially benefit from the results of this research. This interest has been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. The other authors declare no competing interests.
